| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(1 year, 3 months from now) | |
| US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(1 year, 3 months from now) | |
| US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(2 years from now) | |
| US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(7 years from now) | |
| US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(7 years from now) | |
| US8952065 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Feb, 2035
(10 years from now) | |
Acetadote is owned by Cumberland Pharms.
Acetadote contains Acetylcysteine.
Acetadote has a total of 6 drug patents out of which 0 drug patents have expired.
Acetadote was authorised for market use on 23 January, 2004.
Acetadote is available in injectable;intravenous dosage forms.
Acetadote can be used as composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy, method of treating acetaminophen overdose with acetylcysteine solutions.
The generics of Acetadote are possible to be released after 10 February, 2035.
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE;INTRAVENOUS
ACETADOTE family patents
